Immutep Ltd · ASX:IMM

Immutep — 34. Deutscher Krebskongress (February 2020)

12 slides from Immutep's conference presentation, Feb 19, 2020

  1. Slide 1: Initial results from Phase II TACTI-002 study in NSCLC and HNSCC

    Initial results from a Phase II study (TACTI-002) in metastatic non- small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab 34. Deutscher Krebskongress Dr. B. Doger 19 Feb 2020

  2. Slide 2: Notice: Forward Looking Statements

    Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cla

  3. Slide 3: Eftilagimod alpha (efti): Innovative LAG-3 I-O Product Candidate

    Eftilagimod alpha (efti) Innovative LAG-3 I-O Product Candidate • Efti is a soluble LAG-3 protein targeting a subset of MHC class II on APC • Potentially synergistic with other therapeutic agents, e.g. I-O agents or chemotherapies “PUSHING THE ACCELERATOR ON IMMUNE RESPONSES” “RELEASING THE BRAKE ON

  4. Slide 4: Eftilagimod alpha (efti): Mechanism of Action (MoA)

    Eftilagimod alpha (efti): a soluble LAG-3 protein Mechanism of Action (MoA) Efti’s unique agonistic MoA leads to T cell expansion and proliferation → pushing the gas on the immune response Efti binds to MHC class II on monocytes DC/ monocyte activation induced Leads to T cell expansion and prolifera

  5. Slide 5: TACTI-002 Rationale for combination with PD-1 antagonist

    eftilagimod alpha TACTI-002 Rationale combination eftilagimod alpha plus PD-1 antagonist (e.g. pembrolizumab) → Efti increases peripheral monocyte counts in cancer patients Melanoma → Baseline innate immunity status seems to be important for the response (OS) to pembrolizumab → Data suggests that lo

  6. Slide 6: TACTI-002 Trial Design + Introduction

    eftilagimod alpha TACTI-002 Trial Design + Introduction → Phase II, multi-national, open label, Simon`s 2 stage design; PD-L1 all comer → In collaboration with Merck Sharp & Dohme (MSD) Eligiblity Part A: 1st line met. NSCLC • Available tumor 30 mg efti SC tissue + Primary: ORR (iRECIST) • ECOG 0-1

  7. Slide 7: Results 1 – all parts stage 1: Exposure and Safety

    eftilagimod alpha - TACTI-002 Results1 – all parts stage 1 Exposure and Safety Summary TEAEs occurred in > 10 % of pts (N=48 in total) Any Grade Grade 2 Grade 3 Adverse event (PT) • 48 pts were enrolled between Mar 2019 and N (%) N (%) N (%) Jan 2020(1). Pts received median 7 (range 1- 20) efti inje

  8. Slide 8: Results – 1st line NSCLC (part A, stage 1) Baseline Characteristics

    eftilagimod alpha - TACTI-002 Results1 - 1st line NSCLC (part A, stage 1) Baseline Characteristics → PD-L1 distribution as expected → PD-L1 all comer trial → Patients are typical NSCLC 1st line pts Baseline Parameters (n=17) N (%) Median age, yrs (range) 65 (53 – 76) Central assessment of tumor cell

  9. Slide 9: 1st line NSCLC (part A, stage 1) Responses and Waterfall plot

    eftilagimod alpha - TACTI-002 Results1 - 1st line NSCLC (part A, stage 1) Responses and Waterfall plot → 47.1 % iORR acc. to iRECIST in this PD-L1 all comer trial → Responses in all PD-L1 subgroups Tumor response - BOR N (%) 100 Part A* - 1st line NSCLC Best response: as per iRECIST Total (N=17) iPD

  10. Slide 10: 1st line NSCLC (part A, stage 1) Spiderplot

    eftilagimod alpha - TACTI-002 Results1 - 1st line NSCLC (part A, stage 1) Spiderplot → At data cut-off 10 pts (59 %) still under treatment at 7+ months → median PFS not yet reached 100 Part A* - 1st line NSCLC Best response: % change compared to start of therapy 80 iPD 60 iSD Main reason for discont

  11. Slide 11: 2nd line HNSCC (part C, stage 1) Responses and Waterfall plot

    eftilagimod alpha - TACTI-002 Results1 – 2nd line HNSCC (part C, stage 1) Responses and Waterfall plot → Initial iORR of 33.3 % in this PD-L1 all comer HNSCC 2nd line patients • Median Age of 66, mostly male (94 %) Part C* - 2nd line HNSCC • ECOG 1 in 47 % 100 Best response: • Different subtypes iPD

  12. Slide 12: Thank you!

    Thank you!

Immutep — 34. Deutscher Krebskongress (February 2020) on 6ix